4 Einträge gefunden

1. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial

   1. Döhner, Hartmut
   2. Weber, Daniela
   3. Krzykalla, Julia
   4. Fiedler, Walter
   5. Kühn, Michael W M
   6. Schroeder, Thomas
   7. Mayer, Karin

   2023 - Forschungsinformationssystem des UKE
2. Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin

   1. Teich, Katrin
   2. Krzykalla, Julia
   3. Kapp-Schwoerer, Silke
   4. Gaidzik, Verena I
   5. Schlenk, Richard F
   6. Paschka, Peter
   7. Weber, Daniela

   2021 - Forschungsinformationssystem des UKE
3. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

   1. Schlenk, Richard F
   2. Paschka, Peter
   3. Krzykalla, Julia
   4. Weber, Daniela
   5. Kapp-Schwoerer, Silke
   6. Gaidzik, Verena I
   7. Leis, Claudia

   2020 - Forschungsinformationssystem des UKE
4. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis

   1. Shahnaz Syed Abd Kadir, Sharifah
   2. Christopeit, Maximilian
   3. Wulf, Gerald
   4. Wagner, Eva
   5. Bornhauser, Martin
   6. Schroeder, Thomas
   7. Crysandt, Martina

   2018 - Forschungsinformationssystem des UKE